Emyria Ltd (AU:EMD) has released an update.
Emyria Ltd has made significant strides in mental health innovation by starting MDMA-Assisted Therapy (MDMA-AT) trials and opening its inaugural Empax Centre. The company has also advanced in the development of its patented MDMA analogue program and has successfully secured grants to support its initiatives. These developments highlight Emyria’s commitment to addressing the urgent need for new treatments in mental health care.
For further insights into AU:EMD stock, check out TipRanks’ Stock Analysis page.